vs
RECURSION PHARMACEUTICALS, INC.（RXRX）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是RECURSION PHARMACEUTICALS, INC.的4.0倍（$140.6M vs $35.5M），VERACYTE, INC.净利率更高（29.3% vs -304.2%，领先333.5%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 18.5%），VERACYTE, INC.自由现金流更多（$48.8M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 20.5%）
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
RXRX vs VCYT — 直观对比
营收规模更大
VCYT
是对方的4.0倍
$35.5M
营收增速更快
RXRX
高出663.2%
18.5%
净利率更高
VCYT
高出333.5%
-304.2%
自由现金流更多
VCYT
多$96.1M
$-47.3M
两年增速更快
RXRX
近两年复合增速
20.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.5M | $140.6M |
| 净利润 | $-108.1M | $41.1M |
| 毛利率 | 59.8% | 72.5% |
| 营业利润率 | -304.8% | 26.4% |
| 净利率 | -304.2% | 29.3% |
| 营收同比 | 681.7% | 18.5% |
| 净利润同比 | 39.6% | 704.8% |
| 每股收益（稀释后） | $-0.17 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RXRXVCYT
| Q4 25 | $35.5M | $140.6M | ||
| Q3 25 | $5.2M | $131.9M | ||
| Q2 25 | $19.2M | $130.2M | ||
| Q1 25 | $14.7M | $114.5M | ||
| Q4 24 | $4.5M | $118.6M | ||
| Q3 24 | $26.1M | $115.9M | ||
| Q2 24 | $14.4M | $114.4M | ||
| Q1 24 | $13.8M | $96.8M |
净利润RXRXVCYT
| Q4 25 | $-108.1M | $41.1M | ||
| Q3 25 | $-162.3M | $19.1M | ||
| Q2 25 | $-171.9M | $-980.0K | ||
| Q1 25 | $-202.5M | $7.0M | ||
| Q4 24 | $-178.9M | $5.1M | ||
| Q3 24 | $-95.8M | $15.2M | ||
| Q2 24 | $-97.5M | $5.7M | ||
| Q1 24 | $-91.4M | $-1.9M |
毛利率RXRXVCYT
| Q4 25 | 59.8% | 72.5% | ||
| Q3 25 | -183.8% | 69.2% | ||
| Q2 25 | -4.9% | 69.0% | ||
| Q1 25 | -48.0% | 69.5% | ||
| Q4 24 | -181.4% | 66.4% | ||
| Q3 24 | 53.7% | 68.2% | ||
| Q2 24 | 36.2% | 68.1% | ||
| Q1 24 | 19.1% | 64.5% |
营业利润率RXRXVCYT
| Q4 25 | -304.8% | 26.4% | ||
| Q3 25 | -3327.6% | 17.4% | ||
| Q2 25 | -916.8% | -4.0% | ||
| Q1 25 | -1297.9% | 2.5% | ||
| Q4 24 | -4042.4% | 3.5% | ||
| Q3 24 | -377.1% | 10.4% | ||
| Q2 24 | -697.4% | 4.0% | ||
| Q1 24 | -698.4% | -4.8% |
净利率RXRXVCYT
| Q4 25 | -304.2% | 29.3% | ||
| Q3 25 | -3135.3% | 14.5% | ||
| Q2 25 | -894.2% | -0.8% | ||
| Q1 25 | -1373.3% | 6.2% | ||
| Q4 24 | -3935.5% | 4.3% | ||
| Q3 24 | -367.5% | 13.1% | ||
| Q2 24 | -676.6% | 5.0% | ||
| Q1 24 | -662.4% | -1.9% |
每股收益（稀释后）RXRXVCYT
| Q4 25 | $-0.17 | $0.50 | ||
| Q3 25 | $-0.36 | $0.24 | ||
| Q2 25 | $-0.41 | $-0.01 | ||
| Q1 25 | $-0.50 | $0.09 | ||
| Q4 24 | $-0.56 | $0.07 | ||
| Q3 24 | $-0.34 | $0.19 | ||
| Q2 24 | $-0.40 | $0.07 | ||
| Q1 24 | $-0.39 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $743.3M | $362.6M |
| 总债务越低越好 | $9.6M | — |
| 股东权益账面价值 | $1.1B | $1.3B |
| 总资产 | $1.5B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资RXRXVCYT
| Q4 25 | $743.3M | $362.6M | ||
| Q3 25 | $659.8M | $315.6M | ||
| Q2 25 | $525.1M | $219.5M | ||
| Q1 25 | $500.5M | $186.1M | ||
| Q4 24 | $594.4M | $239.1M | ||
| Q3 24 | $427.6M | $274.1M | ||
| Q2 24 | $474.3M | $235.9M | ||
| Q1 24 | $296.3M | $209.2M |
总债务RXRXVCYT
| Q4 25 | $9.6M | — | ||
| Q3 25 | $11.9M | — | ||
| Q2 25 | $14.2M | — | ||
| Q1 25 | $16.4M | — | ||
| Q4 24 | $19.0M | — | ||
| Q3 24 | $20.5M | — | ||
| Q2 24 | $22.9M | — | ||
| Q1 24 | — | — |
股东权益RXRXVCYT
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $919.1M | $1.2B | ||
| Q1 25 | $933.9M | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $524.6M | $1.2B | ||
| Q2 24 | $584.4M | $1.1B | ||
| Q1 24 | $401.2M | $1.1B |
总资产RXRXVCYT
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.4B | $1.3B | ||
| Q3 24 | $726.5M | $1.3B | ||
| Q2 24 | $775.9M | $1.2B | ||
| Q1 24 | $557.8M | $1.2B |
负债/权益比RXRXVCYT
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-46.1M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $-47.3M | $48.8M |
| 自由现金流率自由现金流/营收 | -133.1% | 34.7% |
| 资本支出强度资本支出/营收 | 3.5% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $-378.3M | $126.6M |
8季度趋势，按日历期对齐
经营现金流RXRXVCYT
| Q4 25 | $-46.1M | $52.6M | ||
| Q3 25 | $-117.4M | $44.8M | ||
| Q2 25 | $-76.4M | $33.6M | ||
| Q1 25 | $-132.0M | $5.4M | ||
| Q4 24 | $-115.4M | $24.5M | ||
| Q3 24 | $-59.2M | $30.0M | ||
| Q2 24 | $-82.2M | $29.6M | ||
| Q1 24 | $-102.3M | $-9.0M |
自由现金流RXRXVCYT
| Q4 25 | $-47.3M | $48.8M | ||
| Q3 25 | $-117.6M | $42.0M | ||
| Q2 25 | $-79.6M | $32.3M | ||
| Q1 25 | $-133.8M | $3.5M | ||
| Q4 24 | $-116.7M | $20.4M | ||
| Q3 24 | $-63.8M | $27.7M | ||
| Q2 24 | $-83.4M | $26.8M | ||
| Q1 24 | $-109.0M | $-11.1M |
自由现金流率RXRXVCYT
| Q4 25 | -133.1% | 34.7% | ||
| Q3 25 | -2272.5% | 31.8% | ||
| Q2 25 | -413.9% | 24.8% | ||
| Q1 25 | -907.4% | 3.1% | ||
| Q4 24 | -2567.7% | 17.2% | ||
| Q3 24 | -244.6% | 23.9% | ||
| Q2 24 | -578.5% | 23.4% | ||
| Q1 24 | -789.9% | -11.5% |
资本支出强度RXRXVCYT
| Q4 25 | 3.5% | 2.7% | ||
| Q3 25 | 4.7% | 2.1% | ||
| Q2 25 | 16.4% | 1.0% | ||
| Q1 25 | 12.4% | 1.6% | ||
| Q4 24 | 28.6% | 3.5% | ||
| Q3 24 | 17.5% | 1.9% | ||
| Q2 24 | 8.2% | 2.4% | ||
| Q1 24 | 48.2% | 2.2% |
现金转化率RXRXVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RXRX
暂无分部数据
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
